Lpath gets allowance of patent claims for Sphingomab

By Elaine Rigoli

Tampa, Fla., Aug. 23 - Lpath, Inc. announced the receipt of a Notice of Allowance from the Patent and Trademark Office on an important cancer patent, which will give Lpath coverage for the use of Sphingomab in the treatment of cancer.

Sphingomab is Lpath's monoclonal antibody against sphingosine-1-phosphate, a bioactive lipid that has been validated as a cancer drug target.

The claim gives Lpath broad coverage of any agent that binds to sphingosine-1-phosphate for the treatment of cancer. Another claim specifically covers antibodies or antibody variants in cancer treatment.

Lpath said it has other patents that cover Sphingomab as a potential drug, but this new patent gives Lpath coverage of an important disease indication that has been validated in mouse models of human cancers.

"Lpath's broad and deep intellectual property coverage is now supported by over 26 issued and pending patents," said Scott Pancoast, president and chief executive officer, in a statement.

"This patent, once issued, will allow Lpath to prevent the unlicensed use of Sphingomab and other S1P-binding agents in the treatment of cancer," he added.

Lpath, based in San Diego, develops lipidomic-based therapeutics, an emerging field of medical science whereby bioactive signaling lipids are targeted for treating human diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.